Last summer, the Food and Drug Administration (FDA) released a statement in which it announced that four potential “adverse events of interest” (AEI) had been seen among recipients of Pfizer’s COVID vaccine.
However, The Epoch Times noted in an article on Friday that the FDA has remained strangely silent on the issue since July of 2021.
Last year’s statement explained that the FDA had “detected four potential AEIs in the Medicare healthcare claims database of persons aged 65 years and older who had received the Pfizer/BioNTech COVID-19 vaccine.”
Including heart problems
“The four potential AEI are pulmonary embolism, acute myocardial infarction, immune thrombocytopenia, and disseminated intravascular coagulation,” it continued.
The statement stressed that the AEIs in question had not been documented among those who received the other two available vaccines at the time.
“These four events may not be true safety concerns, and the screening method cannot establish that the vaccine caused these AEI,” it cautioned.
“FDA is sharing the initial findings of this safety study in the spirit of transparency but does not believe there is a cause for concern,” the statement added.
It pointed out how “[t]here are alternative explanations for the findings, including the fact that the Pfizer/BioNTech vaccine was given to many high-risk individuals who were older and had significant co-morbidities.”
“FDA continues to closely monitor the safety of the COVID-19 vaccines and will further investigate these findings by conducting more rigorous epidemiological studies,” the statement declared.
Additional information “is expected later this fall
It concluded by pledging that the “FDA will share further updates and information with the public as they become available.”
According to the Times, it recently contacted the FDA to inquire when the agency plans to release its updated findings on Pfizer’s COVID vaccine. “The medical record review and statistical analyses have recently been completed, and the overall study results are currently under internal review at FDA,” a spokesperson told the Times in an email.
“Release of the study findings is expected later this fall,” the spokesperson added. Meanwhile, Pfizer did not respond to a request for comment.